Loading...
NPI 1134346687 · Burlington, VT · Methadone Clinic
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Howard Center Inc is a methadone clinic provider located in Burlington, Vermont. This profile covers 2 Medicare and 16 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Howard Center Inc |
| Address | 855 Pine St |
| City | Burlington |
| State | VT |
| ZIP | 05401 |
| Taxonomy | Methadone Clinic |
| NPI Enumerated | April 19, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $35M |
| Medicare | $517.9K |
HOWARD CENTER INC operates as a medication-assisted treatment/methadone clinic: its Medicare and Medicaid billing is dominated by methadone administration and bundled opioid treatment program services (G2067, described as the weekly MAT bundle) and by methadone dispensing under H0020, plus material buprenorphine codes. The presence of codes for take-home methadone (G2078) and multiple buprenorphine strengths (J0574, J0575, J0572) indicates a mixed model of supervised dosing, take-home supplies, and medication-assisted pharmacotherapy rather than only counseling-only services.
Medicare revenue is highly concentrated: the top 3 Medicare codes by revenue account for 100.0% of this provider's total Medicare revenue, with G2067 alone representing 90.3% and G2078 9.7% of Medicare receipts. This concentration shows Medicare activity is effectively limited to opioid treatment program bundles and associated take-home dosing rather than a broader set of Medicare service lines.
Medicaid revenue is even more concentrated around medication administration: the top 3 Medicaid codes by revenue account for 91.9% of this provider's total Medicaid revenue, and H0020 (methadone administration and/or service) comprises 81.8% of Medicaid revenue. The next two Medicaid revenue drivers are buprenorphine-related J0574 (5.1%) and J0575 (5.0%), confirming that Medicaid receipts are driven overwhelmingly by addiction-medication dispensing and administration.
Payer mix is heavily skewed to Medicaid: lifetime Medicaid revenue of $35M dwarfs Medicare revenue of $517.9K, so the organization is effectively Medicaid-centric for scale and reimbursement exposure. Analysts should treat Medicare as a minor revenue stream and focus competitive/operational analysis primarily on Medicaid patterns and state program dynamics.
National competitive standing on the Medicare side is solid but not extreme: G2067 ranks #48 of 830 providers nationally (94th percentile) and is labeled as typical, unremarkable volume, while G2078 ranks #29 of 493 (94th percentile) and is also described as typical, unremarkable volume. These ranks indicate HOWARD CENTER is a meaningful national participant among Medicare-enrolled opioid treatment programs but not an extreme outlier in volume or utilization.
State-level competitive standing on Medicaid shows leadership in methadone administration: H0020 ranks #2 of 9 providers in-state (88th percentile) and is characterized as typical, unremarkable volume, signaling one of the largest methadone administrators in Vermont. Buprenorphine products show mid-to-high state ranking as well (J0574 #3 of 7, 67th percentile; J0575 #2 of 7, 83th percentile), supporting a multi-product medication strategy within the state.
Operational footprint is high-volume on daily dosing metrics: H0020 includes 58.6K claims and $28.6M revenue, which is consistent with large-scale, repeated-dosing operations such as daily or frequent clinic dosing and dispensing. The provider also bills for outpatient intensive services and residential/sub-acute detox codes (H0015, H0010), indicating an array of treatment intensities beyond dispensing alone and a capacity to deliver both medication and psychosocial interventions.
HOWARD CENTER has long tenure in the provider population, with NPI enumerated 2007-04-19 (~19 years ago), which supports interpretation of the concentrated billing pattern as an established, focused OTP model rather than a new entrant. A few Medicaid codes (for example H0010 where it is #1 of 1 providers in-state with no peer comparison available) suggest unique service offerings in the state that warrant targeted review for network planning and capacity assessments.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 2,810 | $170 | $466.8K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | 1,320 | $40 | $50K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 2 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 58,630 | $490 | $28.6M |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 8,090 | $220 | $1.8M |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 5,490 | $320 | $1.7M |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including… | 5,560 | $120 | $672.5K |
| H0010 | Alcohol and/or drug services; sub‑acute detoxification (residential addiction program inpatient) | 5,510 | $120 | $666.2K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 6,900 | $90 | $593.7K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 3,970 | $90 | $345K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 3,750 | $80 | $281.5K |
| T1016 | Case management, each 15 minutes | 5,270 | $30 | $131.8K |
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | 460 | $140 | $61.7K |
Showing 1–10 of 16
How this provider's Medicaid billing volume and revenue compare to other Vermont providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Vermont median
16 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 2 | 10 | 17,110 | $40 | $13.6M |
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | 3 | 10 | 3,330 | $2,480 | $11.2M |
| H2017 | Psychosocial rehabilitation services, per 15 minutes | 27 | 30 | 6,730 | $110 | $4.1M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 4 | 10 | 120 | $190 | $4.1M |
| H0010 | Alcohol and/or drug services; sub‑acute detoxification (residential addiction program inpatient) | 1 | 10 | 5,510 | $120 | $664.4K |
| J0575 | Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine | 2 | 10 | 1,360 | $50 | $551.1K |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 3 | 10 | 6,550 | $30 | $483.4K |
| H0015 | Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including… | 3 | 10 | 660 | $120 | $303.7K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 3 | 20 | 1,410 | $80 | $247.4K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 4 | 10 | 630 | $60 | $243.1K |
Showing 1–10 of 16
Other providers in the same ZIP code as Howard Center Inc, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.